Sign in
Taking people in United StatesPhase 1/2

Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease

Key facts

Who runs it
Acepodia Biotech, Inc.
Where
Atlanta and Boston, United StatesSee the 2 sitesAlso in 2 other countries, 9 sites
Trial code
Status
Recruiting
Phase
Phase 1/2
People taking part
34 people, planned
Started
1 Jan 2026
Expected to end
20 Sept 2029
Type of study
Interventional, 2 groups
Treatments tested
  • ACE1831
  • Lymphodepleting chemotherapy
Record updated
2 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Signed Informed Consent
  • Male or female ≥ 18 years of age
  • Active IgG4-RD flare at screening with IgG4-RD Responder Index at least 2, confirmed by symptoms, labs, and/or imaging
  • History of IgG4-RD involving at least 2 organs/sites, and current flare involves at least 1 organ/site (excluding lymph nodes) requiring treatment
  • Elevated serum IgG4 above the upper limit of normal at screening
  • Able to receive glucocorticoids for current flare and taper to 0 mg by Day -5
  • Contraception agreement per protocol from screening through 24 weeks after last ACE1831 dose (no LDC) or 12 months after last LDC dose (with LDC)
  • For sites in China only: prior treatment failure to glucocorticoids, one immunosuppressive agent and one biologic agent

Who cannot take part

  • Recent investigational agent exposure
  • Recent B-cell depleting therapy (anti-CD20/anti-CD19) unless reconstitution per protocol
  • Live/attenuated vaccine within 2 months
  • Significant conditions that impair ability to receive study treatment or comply
  • Active/latent infection that would interfere with therapy (including HBV, HCV, HIV, TB, syphilis) or significant recent infection per protocol
  • NYHA class III/IV heart disease
  • Severe allergy/hypersensitivity to monoclonal antibodies or relevant study agents
  • Malignancy within 5 years (protocol exceptions apply)
  • Inadequate organ function/blood counts per protocol
  • Predominant fibrosis in affected organs
  • Known immunodeficiency state
  • Pregnant or breastfeeding

Where in United States

Also in 2 other countries, 9 sites

  • Emory UniversityAtlanta, United StatesContact: Acepodia Clinical TeamTaking people
  • Massachusetts General HospitalBoston, United StatesContact: Acepodia Clinical TeamTaking people

About the trial

What the trial wants to find out

ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment in subjects with Immunoglobulin G4 Related Disease (IgG4-RD)

The 2 groups in the trial

  • Arm ATreatment being tested

    * Cohort A1: Receives single infusion of ACE1831 (Dose Level 1) with lymphodepletion conditioning (LDC). * Cohort A2: Receives single infusion of ACE1831 (Dose Level 2) with LDC.

    Treatment: ACE1831 and Lymphodepleting chemotherapy

  • Arm BTreatment being tested

    * Cohort B1: Receives two infusions of ACE1831 (Dose Level 1) without LDC. * Cohort B2: Receives two infusions of ACE1831 (Dose Level 2) without LDC. * Cohort E (Expansion): Two infusions of ACE1831 at the dose/regimen selected by the Safety Review Committee (SRC)

    Treatment: ACE1831

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 1b/2a Prospective, Open Label, Multicenter, Two-Arm Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With Immunoglobulin G4-Related Disease
Record updated
2 October 2026